Funding for this research was provided by:
Received: 21 November 2017
Accepted: 3 May 2019
First Online: 13 June 2019
Ethics approval and consent to participate
: Both studies were conducted in accordance with the Declaration of Helsinki (2008), and the protocol and informed consent forms were submitted for approval to institutional review boards. All patients provided written informed consent prior to any study-related procedures. A complete list of participating trial sites and institutional review boards is provided as an additional file.
: Not applicable.
: LS is a consultant/adviser for and has received funding from Eisai Inc., and Helsinn.KM has no conflict of interest to disclose.SW has no conflict of interest to disclose.SP is a consultant for Celldex, MedImmune, Pfizer, AbbVie, AstraZeneca, Eisai, and Puma.JO is a consultant/adviser for Eisai Inc.EB and YH are former employees of Eisai Inc.LV is a consultant/adviser for Eisai Inc., Bristol-Myers Squibb Oncology, and Berg Pharma.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.